Change search
ReferencesLink to record
Permanent link

Direct link
Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data
Quantify Research, Sweden.
Amgen Inc, CA 91320 USA.
Strateg Healthcare Solut LLC, MD USA.
Quantify Research, Sweden; Karolinska Institute, Sweden.
Show others and affiliations
2016 (English)In: European Journal of Health Economics, ISSN 1618-7598, E-ISSN 1618-7601, Vol. 17, no 5, 591-601 p.Article in journal (Refereed) PublishedText
Abstract [en]

To estimate healthcare costs of new cardiovascular (CV) events (myocardial infarction, unstable angina, revascularization, ischemic stroke, transient ischemic attack, heart failure) in patients with hyperlipidemia or prior CV events. A retrospective population-based cohort study was conducted using Swedish national registers and electronic medical records. Patients with hyperlipidemia or prior CV events were stratified into three cohorts based on CV risk level: history of major cardiovascular disease (CVD), coronary heart disease (CHD) risk-equivalent, and low/unknown risk. Propensity score matching was applied to compare patients with new events to patients without new events for estimation of incremental costs of any event and by event type. A CV event resulted in increased costs over 3 years of follow-up, with the majority of costs occurring in the 1st year following the event. The mean incremental cost of patients with a history of major CVD (n = 6881) was a,not sign8588 during the 1st year following the event. This was similar to that of CHD risk-equivalent patients (n = 3226; a,not sign6663) and patients at low/unknown risk (n = 2497; a,not sign8346). Ischemic stroke resulted in the highest 1st-year cost for patients with a history of major CVD and CHD risk-equivalent patients (a,not sign10,194 and a,not sign9823, respectively); transient ischemic attack in the lowest (a,not sign3917 and a,not sign4140). Incremental costs remained elevated in all cohorts during all three follow-up years, with costs being highest in the major CVD history cohort. Healthcare costs of CV events are substantial and vary considerably by event type. Incremental costs remain elevated for several years after an event.

Place, publisher, year, edition, pages
SPRINGER , 2016. Vol. 17, no 5, 591-601 p.
Keyword [en]
Cardiovascular; Costs; Hyperlipidemia; CVD; Resource use; Burden of illness
National Category
Dermatology and Venereal Diseases
URN: urn:nbn:se:liu:diva-129142DOI: 10.1007/s10198-015-0702-0ISI: 000376298900007PubMedID: 26077550OAI: diva2:936063

Funding Agencies|Amgen, Inc.

Available from: 2016-06-13 Created: 2016-06-13 Last updated: 2016-07-07

Open Access in DiVA

fulltext(469 kB)9 downloads
File information
File name FULLTEXT01.pdfFile size 469 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Levin, Lars-Åke
By organisation
Division of Health Care AnalysisFaculty of Medicine and Health Sciences
In the same journal
European Journal of Health Economics
Dermatology and Venereal Diseases

Search outside of DiVA

GoogleGoogle Scholar
Total: 9 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 11 hits
ReferencesLink to record
Permanent link

Direct link